相关实验视频

Updated: Sep 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

对鼻癌的托利帕利马布组合疗法没有同时使用西斯普拉丁: DIAMOND随机临床试验

, Cheng Xu¹, Xiao-Yu Liang¹

¹Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, People's Republic (PR) of China.

|August 21, 2025

概括

在不同时使用西斯普拉丁的托里帕利马布免疫疗法对鼻癌 (NPC) 有效且安全. 这种方法显著减少吐,改善生活质量,同时保持无故障生存.

科学领域:

癌症学
免疫疗法
临床试验

背景情况:

鼻癌 (NPC) 的治疗通常涉及有毒的同时使用西斯.
使用toripalimab对编程细胞死亡蛋白1 (PD-1) 的阻断提供了一个潜在的替代方案.

研究的目的:

评估托利帕利马布与诱导化疗和放射治疗结合的疗效和安全性,同时省略西斯普拉丁,用于局部高级NPC.
评估与标准治疗相比,这种策略是否会影响生存.

主要方法:

一项3期,开放式,多中心的随机临床试验 (NCT04907370) 涉及532名局部发达NPC患者.
患者接受了诱导化疗和放射治疗,其中一组同时接受西斯,另一组不接受.
主要终点是无故障存活率和所有级别吐的发生率.

主要成果:

同时使用思普拉丁的小组表现出非较低的无衰竭生存率 (88. 3% vs 87. 6% 在3年).
在不服用西斯普拉丁的组中,所有级别的吐发生率明显较低 (26. 2% vs 59. 8%).
患者报告的改善生活质量和耐受性在西斯普拉丁节省组中观察到.

结论:

没有同步使用西斯普拉丁的托里帕利马布联合治疗是一种可行的,高效的治疗方法.
这种方法可以实现高无故障存活率,并显著降低毒性,特别是吐.
这些发现支持在该患者群体中省略并发性思普拉丁,以改善治疗经验和结果.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...